MEOBF
MESOBLAST LTD
$1.55
-8.82%
No data for this timeframe.
Vol
SEC Reports7
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. C3·CIK 0001345099·Prev Close $1.70
Recent Activity
Apr 30, 2026
SEC
Mesoblast reported Q3 FY2026 Ryoncil net revenues of US$30.3M and a reduced net operating cash spend of US$4.1M, with ca
6-K — Impact 6/10
Apr 17, 2026
SEC
Mesoblast Limited filed an 8-K with the SEC to report insider transactions, including on-market purchases of American De
6-K — Impact 3/10
Apr 15, 2026
SEC
Mesoblast Limited has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology p
6-K — Impact 6/10
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Latest Reports
BULLISH
6-K
6/10
Mesoblast reported Q3 FY2026 Ryoncil net revenues of US$30.3M and a reduced net operating cash spend of US$4.1M, with ca
Apr 30, 2026
NEUTRAL
6-K
3/10
Mesoblast Limited filed an 8-K with the SEC to report insider transactions, including on-market purchases of American De
Apr 17, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.4/10.
BULLISH
6-K
6/10
Mesoblast reported Q3 FY2026 Ryoncil net revenues of US$30.3M and a reduced net operating cash spend
Apr 30, 2026
NEUTRAL
6-K
3/10
Mesoblast Limited filed an 8-K with the SEC to report insider transactions, including on-market purc
Apr 17, 2026
BULLISH
6-K
6/10
Mesoblast Limited has acquired an exclusive worldwide license to a patented chimeric antigen recepto
Apr 15, 2026
BULLISH
6-K
7/10
Mesoblast hosted an R&D Day event highlighting commercial progress of its FDA-approved product Ryonc
Apr 8, 2026
BULLISH
6-K
7/10
Mesoblast received FDA clearance to proceed directly to a registrational trial for Ryoncil in Duchen
Apr 8, 2026
BULLISH
6-K
7/10
Mesoblast Limited announced strong net sales of US$30.3 million for Ryoncil in the March quarter, wi
Apr 8, 2026
NEUTRAL
6-K
2/10
Mesoblast Ltd filed an announcement with the Australian Securities Exchange regarding a new issue of
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 90% buy across 10 analysts — 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | — | — |
| Current FY 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 572.1% | — |
| Next FY 2027-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | 73.3% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 16, 2026
Clinical Trial
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
Phase Phase 2 — TERMINATED
May 16, 2026
Clinical Trial
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
Phase Phase 2 — TERMINATED
Apr 1, 2026
Clinical Trial
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Phase Phase 3 — COMPLETED